185961-99-3

Basic information

• Product Name: 1-(piperidin-4-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
• Synonyms: 1-(piperidin-4-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;2H-IMidazo[4,5-b]pyridin-2-one, 1,3-dihydro-1-(4-piperidinyl)-;1-Piperidin-4-yl-1,3-dihydro-iMidazo[4,5-b]pyridin-2-one;1-(Piperidin-4-yl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one;1,3-dihydro-1-(4-piperidinyl)-2h-imidazo[4,5-b]pyridin-2-one;185961-99-3
• CAS NO: 185961-99-3
• Molecular Formula: C₁₁H₁₄N₄O
• Molecular Weight: 218.25506
• Mol File: 185961-99-3.mol

Chemical Properties

• Appearance: /
• Density: 1.272g/cm³
• Refractive Index: 1.601
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 1-(piperidin-4-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(piperidin-4-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one(185961-99-3)
• EPA Substance Registry System: 1-(piperidin-4-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one(185961-99-3)

Safety Data

• Hazardous Substances Data: 185961-99-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(piperidin-4-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one is used as a potential active pharmaceutical ingredient for the development of new drugs. Its complex structure suggests that it may interact with biological targets in unique ways, potentially leading to novel therapeutic applications.
Used in Biochemical Research:
In the field of biochemistry, 1-(piperidin-4-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one is used as a research tool to study molecular interactions and mechanisms. Its heterocyclic and diazole components may provide insights into the binding and activity of various biomolecules, contributing to the advancement of biochemical knowledge.
Used in Drug Design and Development:
1-(piperidin-4-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one is employed as a lead compound in drug design and development. Its structural features may offer a starting point for the creation of new drugs with specific therapeutic effects, pending further investigation into its pharmacological properties and safety profile.

InChI:InChI=1/C11H14N4O/c16-11-14-10-9(2-1-5-13-10)15(11)8-3-6-12-7-4-8/h1-2,5,8,12H,3-4,6-7H2,(H,13,14,16)

Upstream product

• 19099-93-5 benzyl 4-oxo-1-piperidinecarboxylate 

Downstream Products

• 1095273-42-9 1-[1-({5-[3-chloro-5-(methyloxy)phenyl]-1,3,4-oxadiazol-2-yl}acetyl)-4-piperidinyl]-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one 
• 1095273-39-4 1-(1-{[5-(5-chloro-3-biphenylyl)-1,3,4-oxadiazol-2-yl]acetyl}-4-piperidinyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one 
• 1095273-52-1 1-[1-({5-[3-methyl-5-(4-morpholinyl)phenyl]-1,3,4-oxadiazol-2-yl}acetyl)-4-piperidinyl]-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one 
• 1219921-64-8 C₃₁H₃₁N₇O₄ 
• 1219921-59-1 C₂₁H₁₉ClN₆O₃ 
• 1219921-61-5 C₂₁H₁₈Cl₂N₆O₃ 
• 1095273-50-9 1-(1-{[5-(2,5-dichlorophenyl)-1,3,4-oxadiazol-2-yl]acetyl}-4-piperidinyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one 
• 1219921-62-6 C₂₁H₁₈Cl₂N₆O₃ 
• 1219921-63-7 C₂₁H₁₈Cl₂N₆O₃ 
• 1095273-46-3 1-(1-{[5-(3,5-dichlorophenyl)-1,3,4-oxadiazol-2-yl]acetyl}-4-piperidinyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one 
• 1095273-49-6 1-(1-{[5-(3,5-difluorophenyl)-1,3,4-oxadiazol-2-yl]acetyl}-4-piperidinyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one 
• 1095273-60-1 1-(1-{[5-(3,5-dimethylphenyl)-1,3,4-oxadiazol-2-yl]acetyl}-4-piperidinyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one 
• 1095273-59-8 1-[1-({5-[3,5-bis(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-yl}acetyl)-4-piperidinyl]-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one 
• 1095273-56-5 1-[1-({5-[3,5-bis(methyloxy)phenyl]-1,3,4-oxadiazol-2-yl}acetyl)-4-piperidinyl]-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one 

Relevant articles and documents

Novel Compounds

The present invention relates to the new compounds of general formula I wherein A, U, V, X, Y, R1, R2 and R3 are defined as stated hereinafter, the tautomers, the isomers thereof, the diastereomers, the enantiomers, the hydrates, the mixtures and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, their use and processes for preparing them.

CGRP ANTAGONISTS

The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R1, R2 and R3 are defined as stated hereinafter, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

NOVEL COMPOUNDS

The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R1, R2, R3 and R4 are defined as mentioned in the description, the tautomers thereof, the isomers thereof, the diastereomers thereof, the enantiomers thereof, the hydrates thereof, the mixtures thereof and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, the use thereof and processes for the preparation thereof.